Table 2.
Pharmaceutical costs for placebo and percutaneous coronary intervention (PCI) groups using data from the ORBITA trial
| Drug | ORBITA protocol dose | PCI | Placebo | ||
| Proportion taking | Mean weekly cost | Proportion taking | Mean weekly cost | ||
| Aspirin | 75 mg OD | 0.99 | £0.13 | 0.97 | £0.13 |
| Atorvastatin | ≥40 mg OD | 0.97 | £0.23 | 0.96 | £0.23 |
| Clopidogrel* | 75 mg OD | 1.00 | £0.33 | 0.98 | £0.32 |
| Perindopril* (if known hypertension) | ≥4 mg OD | 0.81 | £0.43 | 0.79 | £0.42 |
| Bisoprolol* | ≥5 mg OD | 0.81 | £0.12 | 0.76 | £0.11 |
| Amlodipine* | ≥5 mg OD | 0.91 | £0.15 | 0.89 | £0.14 |
| Isosorbide mononitrate slow-release* | 25 mg OD | 0.66 | £0.16 | 0.66 | £0.16 |
| Nicorandil | 10 mg BD | 0.48 | £0.38 | 0.59 | £0.47 |
| Ranolazine | 500 mg BD | 0.07 | £0.76 | 0.14 | £1.63 |
| Mean weekly total cost | £2.69 | £3.62 | |||
*= or equivalent.
BD, twice daily; OD, once daily; ORBITA trial, Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial.